TRANSDERM SCOP Drug Patent Profile
✉ Email this page to a colleague
When do Transderm Scop patents expire, and when can generic versions of Transderm Scop launch?
Transderm Scop is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.
The generic ingredient in TRANSDERM SCOP is scopolamine. There are twenty-one drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the scopolamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Transderm Scop
A generic version of TRANSDERM SCOP was approved as scopolamine by PADAGIS US on January 30th, 2015.
US Patents and Regulatory Information for TRANSDERM SCOP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | TRANSDERM SCOP | scopolamine | SYSTEM;TRANSDERMAL | 017874-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
